Trexquant Investment LP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.

Quarter-by-quarter ownership
Trexquant Investment LP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,380,127
+19.8%
114,663
+13.1%
0.11%
+14.6%
Q2 2023$3,657,678
+48.6%
101,405
+57.3%
0.10%
+41.2%
Q1 2023$2,462,033
+729.0%
64,468
+765.1%
0.07%
+385.7%
Q1 2022$297,000
-63.7%
7,452
-63.3%
0.01%
-72.5%
Q4 2021$818,000
+305.0%
20,331
+309.5%
0.05%
+218.8%
Q3 2021$202,000
-80.2%
4,965
-77.9%
0.02%
-81.4%
Q2 2021$1,022,000
+27.9%
22,504
+17.4%
0.09%
+17.8%
Q1 2021$799,000
-1.2%
19,173
-37.7%
0.07%
+40.4%
Q3 2020$809,000
-30.6%
30,794
-29.1%
0.05%
-35.8%
Q2 2020$1,165,000
+8.8%
43,440
-27.0%
0.08%
+3.8%
Q1 2020$1,071,000
-43.9%
59,518
-44.7%
0.08%
-31.0%
Q4 2019$1,909,000
+822.2%
107,645
+844.5%
0.11%
+606.2%
Q3 2018$207,000
-15.9%
11,397
-9.3%
0.02%
-5.9%
Q1 2018$246,000
+9.8%
12,559
-2.8%
0.02%
-69.6%
Q3 2017$224,000
-64.3%
12,915
-73.4%
0.06%
-30.9%
Q1 2017$628,000
+81.5%
48,466
+38.4%
0.08%
+47.3%
Q4 2016$346,000
+58.0%
35,009
+38.1%
0.06%
+89.7%
Q2 2016$219,000
-65.2%
25,345
-61.9%
0.03%
-60.8%
Q1 2016$630,000
+40.0%
66,550
+156.5%
0.07%
+85.0%
Q4 2015$450,000
+109.3%
25,944
+61.7%
0.04%
+110.5%
Q3 2015$215,000
-52.2%
16,041
-49.2%
0.02%
-58.7%
Q1 2015$450,000
-66.7%
31,573
-77.4%
0.05%
-80.8%
Q4 2014$1,350,000139,9550.24%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders